BioPharmaceuticals Australia
The TRI will be one of the few places in the world that can turn research discoveries into real-world treatments for patients. This, Hughes says, is a turning point in the development of Queensland’s biotechnology industry.” “The Queensland Government’s Queensland biotechnology strategic plan 2005-2015: biotechnology-setting new horizons outlines measures to assist the industry reach its projected growth of achieving A$4 billion in revenues and employing over 16,000 Queenslanders in an industry worth A$20 billion by 2025. What our facility will do is allow local companies to make the relatively small quantities of biopharmaceuticals needed for early-stage clinical trials, as well as scale-up their processes and take them right through to market. That is significant. This is a game-changer here locally. We will give home-grown companies the tools they need to compete, enabling Australia to reap the downstream value of its biomedical discoveries and deliver more revolutionary drugs to the world. The Australian biotech industry is rapidly growing. This is an exciting time.” BPA’s state-of-the art facility will house cutting-edge technologies for manufacture of biological drugs
DSM Biologics DSM Biologics has entered into a partnership with BioPharmaceutical Australia with funding provided by the Federal Government and the Government of Queensland. A primary purpose of the collaboration is to provide local services to Australian biopharmaceutical companies. Australian biopharmaceutical developers will be able to locally manufacture new drug candidates to international standards in preclinical, clinical and commercial phases. This is an important step for the Australian industry. The DSM offering will be an important continuation and expansion of the services we currently provide from our facility in Groningen, The Netherlands. Clients will have the added advantage of being able to choose between standard technology processes or DSM’s proprietary XD® and DSP optimization technologies. The facility is being built in Brisbane within the new Queensland Translational Research Institute, a onestop-shop for discovery, production, clinical testing and manufacturing of new biopharmaceuticals. DSM will bring its know-how to Australia to the benefit of the local industry. DSM has 25 years of experiences in transferring modern technologies and knowhow to other locations inside and outside of the Netherlands.
4